-
Endorsement of HIV misconceptions over time among females and males in Haiti HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-02-23 Roger Antabe, Yujiro Sano
To address high HIV prevalence rates in Haiti, disseminating information about HIV transmission has been emphasized. Yet, after several decades, we do not know how effective HIV information dissemi...
-
Participant experiences in a combination HIV cure-related trial with extended analytical treatment interruption in San Francisco, United States HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-02-13 Karine Dubé, Samuel O. Ndukwe, Ana Korolkova, Lynda Dee, Jeremy Sugarman, John A. Sauceda
There is limited systematic information available about the perspectives of participants enrolled in intensive combination HIV cure-related trials inclusive of an extended analytical treatment inte...
-
Staff perspectives on the feasibility of the person-centered care assessment tool (PCC-at) in HIV treatment settings in Ghana: a mixed-methods study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-02-13 Jessica E. Posner, Henry Tagoe, Amy Casella, Caitlin Madevu-Matson, Malia Duffy, Melissa Sharer, Henry Nagai
Person-centered care (PCC) aims to improve client’s experiences in HIV care while advancing outcomes. This study team developed the PCC assessment tool (PCC-AT) to assess PCC service performance in...
-
HIV/AIDS knowledge and attitudes towards HIV and condom use among internally displaced Libyan males. Is there a need to implement sex education? HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-01-25 Fauzi Elamouri, Jürgen Kurt Rockstroh, Worapath Kratoo, Yuka Miyahara, Tepanata Pumpaibool
Displacement has been associated with an increased risk of HIV transmission. In light of the lack of data from Libya on sexual behavior and HIV/AIDS knowledge, the effort was undertaken to assess H...
-
Heterogeneity of provider preferences for HIV Care Coordination Program features: latent class analysis of a discrete choice experiment HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-01-22 Chunki Fong, Madellena Conte, Rebecca Zimba, Jennifer Carmona, Gina Gambone, Abigail Baim-Lance, McKaylee Robertson, Mary Irvine, Denis Nash
The PROMISE study assessed revisions designed to facilitate implementation of an HIV care coordination program (CCP) addressing gaps in care and treatment engagement among people living with HIV in...
-
‘The person cutting the path does not know his trail is crooked’. Drawing lessons learned from people accessing antiretroviral treatment services to propose a person-centered care (PCC) minimum practice standard HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-01-22 Malia Duffy, Jessica E. Posner, Caitlin Madevu-Matson, Henry Tagoe, Amy Casella
Introduction: Person-centered care (PCC) in HIV services aims to improve client experiences, advance service accessibility and treatment outcomes and accelerate progress towards epidemic control. F...
-
Health-related quality of life among people living with HIV in the era of universal test and treat: results from a cross-sectional study in KwaZulu-Natal, South Africa HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2024-01-13 Reuben Christopher Moyo, Lovemore N. Sigwadhi, Stanley Carries, Zibuyisile Mkhwanazi, Arvin Bhana, Davide Bruno, Eugene L. Davids, Marie-Claire Van Hout, Darshini Govindasamy
The World Health Organisation’s (WHO) key population-based strategy for ending the human immunodeficiency virus (HIV) epidemic is universal HIV test and treat (UTT) along with pre-exposure prophyla...
-
Determinants of late presentation of HIV positive individuals: a study in Kosovo HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-12-27 Ilir Tolaj, Murat Mehmeti, Hatixhe Gashi, Arabana Kasumi
In recent years, the global response to the HIV/AIDS pandemic has encountered significant challenges, impeding the collective aim of eliminating AIDS as a public health threat by 2030. A major conc...
-
Unannounced phone-based pill counts for monitoring antiretroviral medication adherence in South Africa HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-11-02 Seth Kalichman, Ellen Banas, Bruno Shkembi, Moira Kalichman, Catherine Mathews
Unannounced phone-based pill counts (UPC) are an objective measure of medication adherence that may be used in resource limited settings. The current study reports the feasibility and validity of U...
-
Impact TB co-infections on immune tolerance among people living with HIV: a systematic review HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-11-02 Yimam Getaneh, Siti qamariyah Khairunisa, Dominicus Husada, Kuntaman Kuntaman, Maria Inge Lusida
The high-burden regions of Sub-Saharan Africa, which accounted for greater than 70% of the HIV epidemic, are disproportionately affected by the high rates of TB coinfection. This might be explained...
-
Participant experiences in HIV cure-directed trial with an extended analytical treatment interruption in Philadelphia, United States HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-10-14 Andrea Bilger, Eion Plenn, Frances K. Barg, Katharine A. Rendle, William B. Carter, Andrea Lamour-Harrington, Nora Jones, Beth Peterson, John A. Sauceda, Pablo Tebas, Karam Mounzer, David Metzger, Luis J. Montaner, Karine Dubé
A feature of HIV cure trials is the need to interrupt treatment to test the efficacy of experimental interventions—a process known as analytical treatment interruptions (ATIs).We report the experie...
-
A telehealth-delivered intervention to extend the veteran HIV treatment cascade for cardiovascular disease prevention: V-EXTRA-CVD study protocol for a randomized controlled trial HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-10-06 Lewis Musoke, Hayden B. Bosworth, Christina Dickson, Pamela Gentry, Elizabeth Strawbridge, Soumya Subramaniam, Jennifer Gierisch, Valerie Smith, Sandra Woolson, John Pura, Willington Amutuhaire, Susanna Naggie, Julie Schexnayder, Karen Hall, Chris T. Longenecker, Nadine M. Harris, Chantrice Rogers, Puja Van Epps, for V-EXTRA-CVD Group
Background: Veterans living with HIV have up to twice the risk of atherosclerotic cardiovascular disease (ASCVD) compared to those without HIV.Objective: Our study seeks to test a non-physician led...
-
Plasma galectin-3 is associated with decreased glomerular filtration rate in chronic HIV HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-10-02 Diana L. Vares-Lum, Louie Mar A. Gangcuangco, Juwon Park, Eduardo Manzano Jr., Michael Ortega, Dominic C. Chow, Cecilia Shikuma
People living with HIV (PLWH) have higher rates of chronic kidney disease (CKD) compared with HIV-uninfected individuals. The pathogenesis of CKD in HIV remains poorly understood but is likely from...
-
Blood and body fluids exposure, post-exposure prophylaxis, and HIV self-testing among healthcare workers in northern Nigeria HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-09-12 Zubairu Iliyasu, Musa Babashani, Khadija Dantata, Shaheed A. Zakariyyah, Muktar A. Gadanya, Humayra A. Bashir, Auwalu U. Gajida, Muktar H. Aliyu
Introduction In high-HIV burden settings, such as Nigeria, HIV self-testing and post-exposure prophylaxis (PEP) are often recommended, but not widely practiced. This study aims to identify the predictors of PEP utilization and preferences for HIV self-testing among healthcare workers in Nigeria. Methods A total of 403 healthcare workers from a tertiary hospital in Nigeria completed questionnaires.
-
An individual community member’s perspective on HIV cure-related research HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-08-24 Thomas J. Villa
Published in HIV Research & Clinical Practice (Vol. 24, No. 1, 2023)
-
Increasing the meaningful involvement of women in HIV cure-related research: a qualitative interview study in the United States HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-08-22 Karine Dubé, Elizabeth Barr, Morgan Philbin, Amaya Perez-Brumer, Brian Minalga, Beth Peterson, Dawn Averitt, Bridgette Picou, Krista Martel, Cecilia Chung, María Mejía, Martha Cameron, Gail Graham, Lynda Dee, Dázon Dixon Diallo, Ebony Gordon, Anastasia Korolkova, Typhanye Dyer, Judith D. Auerbach, Eileen Scully, Krista L. Dong, Sara Gianella
Background Cisgender women represent over half of people living with HIV globally. However, current research efforts toward a cure for HIV focus predominantly on cisgender men. The under-representation of women in HIV cure clinical studies is particularly problematic given data suggesting that sex-dependent phenotypes limit scientific discovery. Objective We aimed to generate considerations to increase
-
‘With this study, we have hope that something is coming’: community members’ perceptions of HIV cure-related research in Durban, South Africa – a qualitative focus group study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-08-09 Karine Dubé, Deli Mthimkhulu, Wiseman Ngcobo, Deborah Mindry, Luyanda Maphalala, Vanessa Pillay, Whitney Tran, Ana Korolkova, Thumbi Ndung’u, Krista Dong
Background Developing a cure for HIV remains a global scientific priority. In 2022, the Females Rising through Education, Support and Health (FRESH) cohort launched an HIV cure-related trial involving an analytical treatment interruption (ATI) in Durban, South Africa. Objectives To explore community perspectives about HIV cure-related research. Methods Between July–August 2022, we conducted three focus
-
Switching to Dolutegravir/lamivudine or Bictegravir/Emtricitabine/Tenofovir alafenamide. A comparative real-world study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-07-26 Hernando Knobel, Esperanza Cañas-Ruano, Ana Guelar, Pablo Knobel, Judit Villar-García, Alicia González-Mena, Ceclia Canepa, Itziar Arrieta-Aldea, Augustin Marcos, Agustí Abalat-Torrres, Roberto Güerri-Fernández
Background This real-world study compared the safety and effectiveness of Dolutegravir/lamivudine (D/L) and Bictegravir/Emtricitabine/Tenefovir alafenamide (B/F/T) switch therapy regimens for people living with HIV (PLWH) Methods The retrospective study conducted from April 2019 to November 2022, included PLWH with < 50 copies/mL of HIV-RNA prior to recruitment who initiated either D/L or B/F/T switching
-
A prediction risk score for HIV among adolescent girls and young women in South Africa: identifying those in need of HIV pre-exposure prophylaxis HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-06-08 Reuben Christopher Moyo, Darshini Govindasamy, Samuel Om Manda, Peter Suwirakwenda Nyasulu
Background In sub-Saharan Africa (SSA), adolescent girls and young women (AGYW) have the highest risk of acquiring HIV. This has led to several studies aimed at identifying risk factors for HIV in AGYM. However, a combination of the purported risk variables in a multivariate risk model could be more useful in determining HIV risk in AGYW than one at a time. The purpose of this study was to develop
-
A prediction risk score for HIV among adolescent girls and young women in South Africa: identifying those in need of HIV pre-exposure prophylaxis. HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-06-03 Reuben Christopher Moyo,Darshini Govindasamy,Samuel Om Manda,Peter Suwirakwenda Nyasulu
BACKGROUND In sub-Saharan Africa (SSA), adolescent girls and young women (AGYW) have the highest risk of acquiring HIV. This has led to several studies aimed at identifying risk factors for HIV in AGYM. However, a combination of the purported risk variables in a multivariate risk model could be more useful in determining HIV risk in AGYW than one at a time. The purpose of this study was to develop
-
Consultations for HIV post-exposure prophylaxis before and after health insurance coverage of pre-exposure prophylaxis to a university-based emergency department in Germany HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-05-07 Lennert Böhm, Björn-Erik Ole Jensen, Hubert Schelzig, Tom Luedde, Michael Bernhard
Background: Potential risk contacts for HIV transmission may lead to presentations to the emergency department (ED) for counseling and initiation of post-exposure prophylaxis (PEP). Objective: To examine the impact of German health insurance covering pre-exposure prophylaxis (PrEP) following Sept 1st 2019 for certain risk groups on the frequency and reasons for PEP counseling in a university-based
-
Incidence of opportunistic infections and its predictors among HIV/AIDS patients on antiretroviral therapy in Gondar University Comprehensive and Specialized Hospital, Ethiopia HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-03-17 Mequanente Dagnaw, Haileab Fekadu, Adhanom Gebre Egziabher, Tesfaye Yesfue, Meera Indracanti, Alemu Tebeje
Introduction: Opportunistic infections (OIs) are the leading cause of morbidity and mortality among adults living with HIV. Current and accurate information about the occurrence of opportunistic infections in HIV-infected adults is critical for developing more effective treatments and interventions. However, few studies have been conducted in Ethiopia on the prevalence of common opportunistic infections
-
Contribution of integrase inhibitor use, body mass index, physical activity and caloric intake to weight gain in people living with HIV HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2023-03-08 Giovanni Guaraldi, Jovana Milic, Elena Bacchi, Federica Carli, Marianna Menozzi, Iacopo Franconi, Alessandro Raimondi, Giacomo Ciusa, Valentina Masi, Michela Belli, Stefano Guaraldi, Emanuele Aprile, Maria Mancini, Cristina Mussini, Jordan E. Lake, Kristine M. Erlandson
Background: Integrase inhibitor (INSTI) use has been associated with greater weight gain (WG) among people living with HIV (PLWH), but it is unclear how this effect compares in magnitude to traditional risk factors for WG. We assessed the population attributable fractions (PAFs) of modifiable lifestyle factors and INSTI regimens in PLWH who experienced a ≥5% WG over follow-up. Methods: In an observational
-
Early switching of tenofovir disoproxil fumarate (TDF) in HIV-infected patients with TDF-induced nephrotoxicity: a prospective study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-09-06 Samadhi Patamatamkul, Nopporn Songumpai, Paruspak Payoong, Pisut Katavetin, Opass Putcharoen
Background: Tenofovir disoproxil fumarate (TDF) can induce proximal renal tubulopathy (PRT) and necessitate changes in treatment regimen. This prospective study aimed to compare tubular function recovery following early switching versus late switching of TDF in human immunodeficiency virus (HIV)-infected patients with TDF-induced PRT. Methods: For this prospective study, conducted during 2017–2019
-
Higher religiosity and spirituality are associated with ethnic group membership among middle-aged and older adults living with HIV HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-08-24 Jeremy D. Delgadillo, Laura M. Campbell, Maria J. Marquine, Anne Heaton, Alexandra S. Rooney, Anya Umlauf, Dilip V. Jeste, David J. Moore, Raeanne C. Moore
Background: HIV is a chronic illness that impacts the lives of more than 1 million people in the United States. As persons living with HIV (PWH) are living longer, it is important to understand the influence that religiosity/spirituality has among middle-aged and older PWH. Objective: Compare the degree of religiosity/spirituality among middle-aged and older PWH and HIV-negative individuals, and to
-
Participant experiences using novel home-based blood collection device for viral load testing in the HIV cure trials with analytical treatment interruptions HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-08-13 Karine Dubé, Harsh Agarwal, William B. Carter, Lynda Dee, Jeff Taylor, Christopher Roebuck, Beth Peterson, Hursch Patel, Samuel Ndukwe, Kenneth M. Lynn, Linden Lalley-Chareczko, Emily Hiserodt, Sukyung Kim, Daniel Rosenbloom, Brad R. Evans, Melanie Anderson, Daria J. Hazuda, Kevin Bateman, Bonnie J. Howell, Livio Azzoni, Karam Mounzer, Pablo Tebas, Luis J. Montaner
Background: HIV cure-directed clinical trials using analytical treatment interruptions (ATIs) require participants to adhere to frequent monitoring visits for viral load tests. Novel viral load monitoring strategies are needed to decrease participant burden during ATIs. Objective: To examine acceptability of a novel home-based blood collection device for viral load testing in the context of two ongoing
-
Adaption of an ongoing clinical trial to quickly respond to gaps in changing international recommendations: the experience of D2EFT HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-08-08 Emmanuelle Papot, Simone Jacoby, Dona Arlinda, Anchalee Avihingsanon, Iskandar Azwa, Margaret Borok, Dannae Brown, Mohamed Cissé, Sounkalo Dao, Nnakelu Eriobu, Richard Kaplan, Muhammad Karyana, Nagalingeswaran Kumarasamy, Johnnie Lee, Marcelo H. Losso, Gail V. Matthews, Leonardo Perelis, Carmen Perez-Casas, Kiat Ruxrungtham, Melynda Watkins, H. Clifford Lane, Anthony Kelleher, Matthew Law, Mark N.
Abstract A rapidly changing landscape of antiretrovirals and their procurement at scale has permitted the evaluation of new optimised second-line antiretroviral therapy (ART) in low- and middle-income countries. D2EFT is an open-label randomised controlled non-inferiority phase IIIB/IV trial in people living with HIV-1 (PWH) whose first-line non-nucleoside reverse transcriptase inhibitor (NNRTI)-based
-
Digital directly observed therapy to monitor adherence to medications: a scoping review HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-07-29 Marie C. D. Stoner, Allysha C. Maragh-Bass, Adam C. Sukhija-Cohen, Parya Saberi
Abstract Background: Technology-based directly observed therapy (DOT) is more cost-effective and efficient compared with in-person monitoring visits for medication adherence. While some evidence shows these technologies are feasible and acceptable, there is limited evidence collating information across medical conditions or in the context of HIV prevention, care, and treatment. Objectives: We conducted
-
Community HIV clinicians’ perceptions about HIV cure-related research in the Northwestern United States HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-07-29 Laurie Sylla, Hursch Patel, Michael Louella, Jane Simoni, Karine Dubé
Abstract Background: Research on stakeholder perspectives of HIV cure research has involved people with HIV (PWH), who generally cite the importance of HIV clinician advice in making decisions about trial participation. However, there has been little exploration of non-researcher community HIV clinician perspectives, which are clearly critical to the success of HIV cure-related research. Objective:
-
Inflammation markers in virologically suppressed HIV-Infected patients after switching to dolutegravir plus lamivudine vs continuing triple therapy: 48-week results in real-life setting HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-06-27 Francesca Lombardi, Simone Belmonti, Davide Moschese, Massimiliano Fabbiani, Alberto Borghetti, Arturo Ciccullo, Elena Visconti, Simona Di Giambenedetto
Objectives: To evaluate the impact of a treatment switch to dolutegravir plus lamivudine on the soluble inflammatory biomarkers of HIV-infected patients treated in a real-life setting. Materials and methods: This was a longitudinal study that enrolled virologically-suppressed patients on stable 3-drug ART who switched at baseline to dolutegravir + lamivudine (2DR-group), based on the clinician’s decision
-
Early infant diagnosis of HIV infection at the John F. Kennedy Medical Center, Monrovia, Liberia HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-06-15 Umar I. U, M. A. Adeiza, R. C. Ideh, O. Ogbuagu
Background: Vertical transmission accounts for majority of new HIV infections among children worldwide. Ninety percent of HIV-positive children reside in Sub- Saharan Africa with their infection predominantly acquired via vertical transmission. In 2004, the vertical transmission rate of HIV in Africa was estimated at 25 − 40% but, remarkably, the rate has significantly decreased to less than 5% in
-
Impact of supervised aerobic exercise on clinical physiological and mental parameters of people living with HIV: a systematic review and meta-analyses of randomized controlled trials HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-03-30 Panagiota Kalatzi, Petros C. Dinas, Costas Chryssanthopoulos, Eleftherios Karatzanos, Serafim Nanas, Anastassios Philippou
Abstract Background: The benefits derived from supervised aerobic exercise in people living with human immunofeficiency virus– HIV (PLWH) have not yet been clearly identified. Objective: To evaluate the impact of supervised aerobic exercise on immunological, cardiorespiratory, pulmonary, hemodynamic and mental parameters of PLWH. Methods: A systematic review was carried out in accordance to PRISMA
-
“We are looking at the future right now”: community acceptability of a home-based viral load test device in the context of HIV cure-related research with analytical treatment interruptions in the United States HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-03-29 Karine Dubé, John Kanazawa, Christopher Roebuck, Steven Johnson, William B. Carter, Lynda Dee, Beth Peterson, Kenneth M. Lynn, Linden Lalley-Chareczko, Emily Hiserodt, Sukyung Kim, Daniel Rosenbloom, Brad R. Evans, Melanie Anderson, Daria J. Hazuda, Lisa Shipley, Kevin Bateman, Bonnie J. Howell, Karam Mounzer, Pablo Tebas, Luis J. Montaner
Abstract Background People with HIV (PWH) and community members have advocated for the development of a home-based viral load test device that could make analytical treatment interruptions (ATIs) less burdensome. Objective We assessed community acceptability of a novel home-based viral load test device. Methods In 2021, we conducted 15 interviews and 3 virtual focus groups with PWH involved in HIV
-
Evaluation of the pharmacokinetic drug-drug interaction between the antiretroviral agents fostemsavir and maraviroc: a single-sequence crossover study in healthy participants HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-03-14 Mary Beth Wire, Mindy Magee, Peter Ackerman, Cyril Llamoso, Katy Moore
Background Fostemsavir is an oral prodrug of temsavir, a first‐in‐class attachment inhibitor that binds HIV‐1 gp120, preventing initial HIV attachment and entry into host immune cells. Objective The pharmacokinetic interaction was determined between temsavir and maraviroc, a CCR5 allosteric inhibitor indicated for CCR5-tropic HIV-1 that may be co-administered with fostemsavir as part of combination
-
Switching to a NRTI-free 2 drug regimen (2DR) –a sub-analysis of the 48 weeks DUALIS study on metabolic and renal changes HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-03-02 Malte Monin, Tim Kümmerle, Jochen Schneider, Christiane Cordes, Hans Heiken, Hans-Jürgen Stellbrink, Ivanka Krznaric, Stefan Scholten, Björn Jensen, Heiko Jessen, Wilfried Obst, Petra Spornraft-Ragaller, Pavel Khaykin, Annamaria Balogh, Eva Wolf, Helen Bidner, Christoph D. Spinner, Christoph Boesecke, on behalf of the DUALIS STUDY GROUP
Abstract Background/Aims: Switching from a three-drug regimen (3DR: boosted darunavir [bDRV] and two nucleoside reverse transcriptase inhibitors [NRTIs]) to a two-drug regimen (2DR: bDRV and dolutegravir [DTG]) demonstrated non-inferiority with regard to viral suppression in people living with HIV (PLWH) in the DUALIS study. This sub-analysis focuses on changes in metabolic and renal parameters when
-
Does antiretroviral therapy change the relationship between body composition and muscle strength in children and adolescents diagnosed with HIV? HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2022-02-22 Priscila Custódio Martins, Carlos Alencar Souza Alves Junior, Luiz Rodrigo Augustemak de Lima, Edio Luiz Petroski, Diego Augusto Santos Silva
Abstract Background: HIV infection and prolonged use of antiretroviral therapy (ART) can impact the body composition and muscle strength of HIV-infected children and adolescents. Therefore, the aim was to verify the association between lean soft tissue mass (LSTM) and handgrip strength (HGS) in children and adolescents diagnosed with HIV using or not using ART (with or without protease inhibitors [PI])
-
Impact of treatment adherence on efficacy of dolutegravir plus lamivudine and dolutegravir plus tenofovir disoproxil fumarate/emtricitabine: pooled analysis of the GEMINI-1 and GEMINI-2 clinical studies HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-12-16 Mounir Ait-Khaled, Juan Sierra Madero, Vicente Estrada, Roberto Gulminetti, Debbie Hagins, Hung-Chin Tsai, Choy Man, Jörg Sievers, Richard Grove, Andrew Zolopa, Brian Wynne, Jean van Wyk
Abstract Background: GEMINI-1 and GEMINI-2 (ClinicalTrials.gov, NCT02831673 and NCT02831764, respectively) are double-blind, multicenter, phase III studies that demonstrated the non-inferiority of once-daily dolutegravir + lamivudine to dolutegravir + tenofovir disoproxil fumarate/emtricitabine in achieving HIV-1 RNA <50 copies/mL at 48, 96, and 144 weeks in treatment-naive adults with HIV-1 infection
-
Cerebral function parameters in people with HIV switching integrase inhibitors: a randomized controlled trial HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-11-08 Borja Mora-Peris, Michael R. Keegan, Sujan Dilly Penchala, Jaime H. Vera, Jonathan Underwood, Maryam Khan, Carolina Herrera, Dietmar Fuchs, Adriano Boasso, Saye Khoo, Alan Winston
Background: Different antiretroviral therapies (ARTs) may have differing effects on central nervous system (CNS) function. We assessed CNS pharmacodynamic effects of switching integrase inhibitors in people-with-HIV (PWH). Methods: PWH on tenofovir-DF/emtricitabine plus raltegravir 400 mg twice daily with suppressed plasma HIV RNA and without overt neuropsychiatric symptoms were randomly allocated
-
Hypersensitivity reactions, hepatotoxicity, and other discontinuations in persons receiving integrase strand transfer inhibitors: results from the EuroSIDA study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-11-15 Annegret Pelchen-Matthews, Jakob Friis Larsen, Leah Shepherd, Josip Begovac, Karen Pedersen, Stéphane De Wit, Andrzej Horban, Elzbieta Jablonowska, Margaret Johnson, Irina Khromova, Marcelo H. Losso, Lars N. Nielsen, Anna Lisa Ridolfo, Brigitte Schmied, Christoph Stephan, Israel Yust, Lloyd Curtis, Vani Vannappagari, Leigh Ragone, Ashley Roen, Dorthe Raben, Ole Kirk, Lars Peters, Amanda Mocroft, for
Background: Hypersensitivity reaction (HSR) and hepatotoxicity are rare, but potentially serious side-effects of antiretroviral use. Objective: To investigate discontinuations due to HSR, hepatotoxicity or other reasons among users of dolutegravir (DTG) vs. raltegravir (RAL) or elvitegravir (EVG) in the EuroSIDA cohort. Methods: We compared individuals ≥18 years and starting combination antiretroviral
-
Effects of resistance training on muscle strength, body composition and immune-inflammatory markers in people living with HIV: a systematic review and Meta-analysis of randomized controlled trials HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-09-25 Hugo R. Zanetti, Leandro T. P. Lopes, Alexandre Gonçalves, Vitor L. Soares, Weverton F. Soares, Adrian V. Hernandez, Gary Tse, Tong Liu, Giuseppe Biondi-Zoccai, Leonardo Roever, Edmar L. Mendes
Purpose: The purpose of this review is to evaluate the effect of resistance training (RT) as a unique intervention on muscle strength, body composition, and immune-inflammatory markers in people living with HIV (PLHIV). Methods: The searches were conducted in seven databases and included published randomized clinical trials that assessed the effect of RT vs. no exercise on muscle strength, body composition
-
A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-09-22 Margherita Bracchi, Nicole Pagani, Alessia Dalla Pria, Ana Milinkovic, Nneka Nwokolo, Lervina Thomas, Sundhyia Mandalia, Marta Boffito, Graeme Moyle
Objectives: Tenofovir DF (TDF) remains one of the preferred backbone agents for naïve HIV patients starting antiretroviral treatment (ART). The impact of TDF on renal function and metabolic parameters may vary by anchor agent. We investigated the impact of TDF in combination with 3 different integrase inhibitors on tubular and glomerular function, and metabolic parameters in ART-naïve patients. Methods:
-
Effects of exercise training on bone mineral density in adults living with HIV: a retrospective study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-09-25 Gabriela Andrade Paz, Paulo Farinatti, Karynne Grutter Lopes, Juliana Pereira Borges
Background: Evidence on the effects of exercise training on the bone health of men and women living with HIV (MLHIV and WLHIV) is limited. Objective: To investigate the effects of a long-term multimodal exercise program on the bone mineral density (BMD) of MLHIV and WLHIV. Methods: A retrospective cohort of 39 patients (13 women; 48.4 ± 7.6 y; HIV-infection for 15.5 ± 6.5 y; combined antiretroviral
-
Neurological manifestations in people living with HIV/AIDS in the late cART era: a prospective observational study at a tertiary healthcare center in São Paulo, Brazil HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-09-16 João Paulo Telles, Ruan Fernandes, Tiago Dahrug Barros, Alvino Maestri, Thiago Vitoriano, Luciana Borges, Ralcyon Teixeira, Rosa Marcusso, Michel Haziot, Augusto Penalva De Oliveira, José Ernesto Vidal
Background:The aim of this study was to evaluate the frequency, spectrum, in-hospital mortality rate, and factors associated with death in people living with HIV/AIDS (PLWHA) presenting with neurological diseases from a middle-income country, as well as estimate its one-year global death rate. Methods:This prospective observational cohort study was conducted at a Brazilian tertiary health center between
-
Early discontinuation of DTG/ABC/3TC and BIC/TAF/FTC single-tablet regimens: a real-life multicenter cohort study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-08-26 Filippo Lagi, Annarita Botta, Arturo Ciccullo, Chiara Picarelli, Massimiliano Fabbiani, Simona di Giambenedetto, Vanni Borghi, Cristina Mussini, Alessandro Bartoloni, Gaetana Sterrantino
Background: Data regarding the efficacy and tolerability of DTG/ABC/3TC/and BIC/TAF/FTC in switching strategies are still scarce. The rates and reasons of early discontinuation within 24 weeks from the switch to dolutegravir (DTG) or bictegravir (BIC) single-tablet regimens (STRs) were compared. Methods: This is a multicenter cohort study. Persons living with HIV (PLWH) with HIV-1 RNA <50 copies/mL
-
HIV and COVID-19: review of clinical course and outcomes HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-09-12 Lauren K. Barbera, Kevin F. Kamis, Sarah E. Rowan, Amelia J. Davis, Soraya Shehata, Jesse J. Carlson, Steven C. Johnson, Kristine M. Erlandson
Background:Understanding the relationship between HIV and SARS-CoV-2 has important public health implications. Objective:To summarize current research on COVID-19 among people with HIV (PWH) as published through 15 July 2021. Methods: We conducted a search of PubMed, Scopus, preprint databases (medRxiv, bioRxiv), and the references of publications found using key terms relevant to COVID-19 (‘COVID-19’
-
Impact of the COVID-19 pandemic situation on HIV care in Liège, Belgium HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-07-25
Background Background: The COVID-19 pandemic and associated containment measures dramatically affected the health care systems including the screening of human immunodeficiency virus and the management people living with HIV around the world by making the access to preventive care services and specific medical monitoring more difficult. Objective Objective: To study the impact of the COVID-19 pandemic
-
Expression of microRNA-155 in circulating T cells is an indicator of immune activation levels in HIV-1 infected patients HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-08-04
Objectives: MicroRNA-155 (miR-155) regulates activation of T cells. However, its relationship with T-cell immune activation level in human immunodeficiency virus (HIV) patients remains unclear. Methods: We recruited 103 HIV-1 infected patients with combination antiretroviral therapy (cART) and 79 cART naïve patients. The miR-155 levels in circulatory T cells were detected by quantitative reverse transcription–PCR
-
eGFR-EPI changes among HIV patients who switch from F/TDF to F/TAF while maintaining the same third agent in the Spanish VACH cohort HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-08-19
Abstract Background: Evidence from clinical practice on the effects of switching from emtricitabine/tenofovir disoproxil fumarate (F/TDF) to emtricitabine/tenofovir alafenamide (F/TAF)-based triple-therapy (TT) regimens on renal parameters is limited. Objective: This retrospective analysis evaluated the effects on renal function of switching from F/TDF to F/TAF-based TT regimens with no change in third
-
Impact of the COVID-19 pandemic situation on HIV care in Liège, Belgium. HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-07-25 Majdouline El Moussaoui,Nicolas Lambert,Nathalie Maes,Karine Fombellida,Dolores Vaira,Michel Moutschen,Gilles Darcis
BACKGROUND Background: The COVID-19 pandemic and associated containment measures dramatically affected the health care systems including the screening of human immunodeficiency virus and the management people living with HIV around the world by making the access to preventive care services and specific medical monitoring more difficult. OBJECTIVE Objective: To study the impact of the COVID-19 pandemic
-
Impact of dedicated women’s outreach workers (WOWs) on recruitment of women in ACTG clinical studies HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-06-18 Elizabeth Barr, Karine Dubé, Shobha Swaminathan, Carlos Del Rio, Danielle M. Campbell, Marta Paez-Quinde, Susan E. Cohn
Background: Despite efforts by the AIDS Clinical Trials Group (ACTG) to enroll representative numbers of diverse women, participation in ACTG studies in the United States remains largely white and male. To address this gap in women’s participation in ACTG research, a one-year pilot study of dedicated women’s outreach workers (WOWs) was proposed. Objectives: included demonstrating that targeted recruitment
-
Dolutegravir-based regimens in treatment-naive and treatment-experienced aging populations: analyses of 6 phase III clinical trials HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-06-28 Frank Spinelli, Manyu Prakash, Jill Slater, Mike van der Kolk, Niccolò Bassani, Richard Grove, Brian Wynne, Jean van Wyk, Andrew Clark
Background: Older adults living with HIV (OALWH) are a growing population facing unique challenges to successful antiretroviral therapy. Objective: To assess efficacy and safety profiles of antiretroviral regimens, including those containing dolutegravir, in OALWH. Methods: Combined data from 6 phase III/IIIb trials in treatment-naive (ARIA, FLAMINGO, SINGLE, SPRING-2; N = 2634) and treatment-experienced
-
Rapid initiation of darunavir/cobicistat/emtricitabine/tenofovir alafenamide in acute and early HIV-1 infection: a DIAMOND subgroup analysis HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-05-17 Keith Dunn, Rachel Rogers, Richard Bruce Simonson, Donghan Luo, Shubin Sheng, Purnima T. Kassam, Sareh Seyedkazemi, Hélène Hardy
Background: Treatment during acute or early human immunodeficiency virus (HIV)-1 infection is associated with immunologic and virologic benefits. Objective: To evaluate darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) efficacy/safety among patients with acute or early HIV-1 infection who rapidly initiate treatment. Methods: DIAMOND (ClinicalTrials.gov Identifier: NCT03227861), a
-
Developing a pilot lifestyle intervention to prevent cardiovascular disease in midlife women with HIV HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-02-21 Greer Raggio, Georgia Goodman, Gregory K. Robbins, Sara E. Looby, Allison Labbe, Christina Psaros
Background Background: Women with HIV (WWH) are at elevated risk for cardiovascular disease (CVD) compared to men with HIV. Lifestyle interventions, like the Diabetes Prevention Program (DPP), may reduce CVD risk, but most fail to address barriers to healthy behaviors facing WWH. Objective Objective: To inform the adaptation of the DPP for midlife WWH, pilot the modified intervention, and assess feasibility
-
Ethical and practical considerations for mitigating risks to sexual partners during analytical treatment interruptions in HIV cure-related research HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-03-24 Karine Dubé, John Kanazawa, Lynda Dee, Jeff Taylor, Danielle M. Campbell, Brandon Brown, Mallory O. Johnson, Parya Saberi, John A. Sauceda, Jeremy Sugarman, Michael J. Peluso
Background Background: Analytical treatment interruptions (ATIs) in HIV cure-related research can result in trial participants becoming viremic with HIV, placing HIV-negative sexual partners at elevated risk of acquiring HIV. Objective Objective:Our study aimed to generate ethical and practical considerations for designing and implementing appropriate risk mitigation strategies to reduce unintended
-
Clinical and angiographical features of first episode of acute coronary syndrome in patients with human immunodeficiency virus infection HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-04-20 Giuseppe Uccello, Rocco Mollace, Maria Stelitano, Annamaria Tavernese, Saverio Muscoli, Marco Di Luozzo, Pasquale De Vico, Francesco Romeo, Valeria Cammalleri
Background Patients affected by the human immunodeficiency virus (HIV) show an increased risk of myocardial infarction. Clinical and angiographic features of HIV positive (HIV+) patients presenting with the first episode of an acute coronary syndrome (ACS) are not well defined in previous studies. Objective To demonstrate that HIV + patients with acute coronary syndrome had different features than
-
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1 HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-02-02 Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective To describe a Week 96 pre-planned subgroup analysis of D/C/F/TAF arms by demographic characteristics (age ≤/>50 years, gender, black/non-black race)
-
Changes in central adipose tissue after switching to integrase inhibitors HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-01-18 Paula Debroy, Han Feng, Hongyu Miao, Jovana Milic, Guido Ligabue, Stefano Draisci, Giulia Besutti, Federica Carli, Marianna Menozzi, Cristina Mussini, Giovanni Guaraldi, Jordan E. Lake
Background: Treatment with integrase strand transfer inhibitors (INSTIs) has been associated with excess weight gain, however the long-term effect of INSTI-based regimens on adipose tissue (AT) compartments remains unknown. Objectives: To evaluate the effect of switching to an INSTI on visceral (VAT) and subcutaneous (SAT) AT in virologically-suppressed adults with HIV. Methods: We performed a retrospective
-
Impact of extended-release niacin on immune activation in HIV-infected immunological non-responders on effective antiretroviral therapy HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-01-06 Bertrand Lebouché, Alexis Yero, Tao Shi, Omar Farnos, Joel Singer, Ido Kema, Cecilia T. Costiniuk, Réjean Thomas, Marie-Josée Brouillette, Kim Engler, Jean-Pierre Routy, Mohammad-Ali Jenabian, for the CTN PT006 Study Group
Background Background: Tryptophan (Trp) catabolism into immunosuppressive kynurenine (Kyn) is involved in immune dysregulation during HIV infection. Niacin (vitamin B3) could control the excess of tryptophan depletion and represents a potential strategy to improve immune functions and CD4 count recovery in immunological non-responder HIV-infected individuals on antiretroviral therapy (ART). Methods
-
Week 96 subgroup analyses of the phase 3, randomized AMBER and EMERALD trials evaluating the efficacy and safety of the once daily darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) single-tablet regimen in antiretroviral treatment (ART)-naïve and -experienced, virologically-suppressed adults living with HIV-1 HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2021-02-02 Gregory D. Huhn, Aimee Wilkin, Cristina Mussini, Christoph D. Spinner, John Jezorwski, Mohsine El Ghazi, Erika Van Landuyt, Erkki Lathouwers, Kimberley Brown, Bryan Baugh, on behalf of the AMBER and EMERALD study groups
Background Darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) 800/150/200/10 mg was investigated in AMBER (treatment-naïve adults; NCT02431247) and EMERALD (treatment-experienced, virologically-suppressed adults; NCT02269917). Objective To describe a Week 96 pre-planned subgroup analysis of D/C/F/TAF arms by demographic characteristics (age ≤/>50 years, gender, black/non-black race)
-
COVID-19 symptoms and SARS-CoV-2 infection among people living with HIV in the US: the MACS/WIHS combined cohort study HIV Res. Clin. Pract. (IF 1.6) Pub Date : 2020-11-19 Gypsyamber D’Souza, Gayle Springer, Deborah Gustafson, Seble Kassaye, Maria L. Alcaide, Catalina Ramirez, Anjali Sharma, Frank J. Palella, Phyllis C. Tien, Roger Detels, Mirjam-Colette Kempf, Cecile D. Lahiri, Charles R. Rinaldo, Audrey L. French, Joseph B. Margolick, Ada A. Adimora
Background SARS-CoV-2 infection among People Living With HIV (PLWH) is not well-described. Objective To study COVID-19 symptoms and SARS-CoV-2 PCR-based swab testing among participants of the Multicenter AIDS Cohort Study (MACS) and Women’s Interagency HIV Study (WIHS). Methods A telephone survey was collected April-June 30, 2020. Symptom and testing prevalence were explored. Multivariable logistic